Newest disclosures first · Trade dates may be earlier
Loading insider disclosures…
Sources & coverage
These are available SEC Form 4 purchase and sale records. The view excludes awards, gifts, option exercises and other transaction types. Large shareholders can include investment firms as well as individuals.
The period follows filing dates. Each row also shows when the transaction occurred. Reported value is shares multiplied by the reported price; a missing or zero imported price is shown as unavailable.
Weekly highlights cover the last seven filing dates and count distinct reporting-owner names. They feature the largest purchase and sale totals among companies with complete amounts in the available records, independently of the filters below.
Coverage is partial. Expand a transaction for the reporting owners, ownership, trading-plan disclosure and footnotes available in that record. Older records may only identify the first reporting owner. Missing context is shown as unavailable; the original filing remains the source.
Role filters use reported officer titles and ownership relationships, so one filing can match more than one role. A purchase transaction code does not establish that a trade took place on the open market.
Position & filing details for Kelley Shannon T, MDGL, filed Nov 6, 2026
Sold 9.4% of reported shares11,474 before → 10,397 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Kelley Shannon T · General Counsel
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 This sale was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2026.
Position & filing details for Foster Jon M, HCA, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
Foster Jon M · EVP and COO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.87 to $514.24, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 Pursuant to a power of substitution, on November 4, 2026, the reporting person transferred 16,142 shares of common stock of the Issuer from a trust to direct ownership in exchange for assets of equal value. The transfer was made at a price per share equal to $503.525 (the average of the high and low prices of shares of common stock of the Issuer on November 4, 2026). The transfer did not change the total number of shares of common stock of the Issuer of which the reporting person may be deemed to have beneficial ownership; however, the shares of common stock previously have been reported by the reporting person as indirectly owned. The reporting person believes that the transfer of shares from the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934.
Position & filing details for Barrocas Mark, SN, filed Nov 6, 2026
Sold 1.4% of reported shares1,678,609 before → 1,654,713 after
Change in this reported direct Ordinary Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Barrocas Mark · Chief Executive Officer · Director
Filing facts
Security
Ordinary Shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.00 to $218.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Position & filing details for Foster Jon M, HCA, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
Foster Jon M · EVP and COO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.87 to $514.24, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 Pursuant to a power of substitution, on November 4, 2026, the reporting person transferred 16,142 shares of common stock of the Issuer from a trust to direct ownership in exchange for assets of equal value. The transfer was made at a price per share equal to $503.525 (the average of the high and low prices of shares of common stock of the Issuer on November 4, 2026). The transfer did not change the total number of shares of common stock of the Issuer of which the reporting person may be deemed to have beneficial ownership; however, the shares of common stock previously have been reported by the reporting person as indirectly owned. The reporting person believes that the transfer of shares from the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934.
Position & filing details for Foster Jon M, HCA, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
Foster Jon M · EVP and COO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.87 to $514.24, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 Pursuant to a power of substitution, on November 4, 2026, the reporting person transferred 16,142 shares of common stock of the Issuer from a trust to direct ownership in exchange for assets of equal value. The transfer was made at a price per share equal to $503.525 (the average of the high and low prices of shares of common stock of the Issuer on November 4, 2026). The transfer did not change the total number of shares of common stock of the Issuer of which the reporting person may be deemed to have beneficial ownership; however, the shares of common stock previously have been reported by the reporting person as indirectly owned. The reporting person believes that the transfer of shares from the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934.
Position & filing details for RUBINSTEIN JULIE, ADPT, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
RUBINSTEIN JULIE · President and COO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.26 to $26.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.26 to $26.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Position & filing details for Foster Jon M, HCA, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
Foster Jon M · EVP and COO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.87 to $514.24, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 Pursuant to a power of substitution, on November 4, 2026, the reporting person transferred 16,142 shares of common stock of the Issuer from a trust to direct ownership in exchange for assets of equal value. The transfer was made at a price per share equal to $503.525 (the average of the high and low prices of shares of common stock of the Issuer on November 4, 2026). The transfer did not change the total number of shares of common stock of the Issuer of which the reporting person may be deemed to have beneficial ownership; however, the shares of common stock previously have been reported by the reporting person as indirectly owned. The reporting person believes that the transfer of shares from the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934.
Position & filing details for An Jing, LKNCY, filed Nov 6, 2026
Sold 6.9% of reported shares245,784 before → 228,784 after
Change in this reported direct American Depositary Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
An Jing · Chief Financial Officer
Filing facts
Security
American Depositary Shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 Each American Depositary Share ("ADS") represents eight Class A Ordinary Shares.
Position & filing details for Barrocas Mark, SN, filed Nov 6, 2026
Sold 0.80% of reported shares1,603,798 before → 1,591,006 after
Change in this reported direct Ordinary Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Barrocas Mark · Chief Executive Officer · Director
Filing facts
Security
Ordinary Shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.00 to $218.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Position & filing details for Barrocas Mark, SN, filed Nov 6, 2026
Sold 0.74% of reported shares1,591,006 before → 1,579,292 after
Change in this reported direct Ordinary Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Barrocas Mark · Chief Executive Officer · Director
Filing facts
Security
Ordinary Shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.00 to $218.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Position & filing details for Barrocas Mark, SN, filed Nov 6, 2026
Sold 0.88% of reported shares1,579,292 before → 1,565,453 after
Change in this reported direct Ordinary Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Barrocas Mark · Chief Executive Officer · Director
Filing facts
Security
Ordinary Shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.00 to $218.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Position & filing details for RUBINSTEIN JULIE, ADPT, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
RUBINSTEIN JULIE · President and COO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.26 to $26.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.26 to $26.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Position & filing details for Barrocas Mark, SN, filed Nov 6, 2026
Sold 0.88% of reported shares1,654,713 before → 1,640,200 after
Change in this reported direct Ordinary Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Barrocas Mark · Chief Executive Officer · Director
Filing facts
Security
Ordinary Shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.00 to $218.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Position & filing details for Sharma Pooja, PRCT, filed Nov 6, 2026
Sold 4.2% of reported shares111,181 before → 106,471 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Sharma Pooja · Chief Strat/Marketing Officer
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 These shares were sold by the reporting person pursuant to the Issuer's sell-to-cover process for tax withholding obligations in connection with the vesting of the Restricted Stock Units on November 5, 2026.
Position & filing details for Barrocas Mark, SN, filed Nov 6, 2026
Sold 1.2% of reported shares1,640,200 before → 1,620,199 after
Change in this reported direct Ordinary Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Barrocas Mark · Chief Executive Officer · Director
Filing facts
Security
Ordinary Shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.00 to $218.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Position & filing details for Barrocas Mark, SN, filed Nov 6, 2026
Sold 1% of reported shares1,620,199 before → 1,603,798 after
Change in this reported direct Ordinary Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Barrocas Mark · Chief Executive Officer · Director
Filing facts
Security
Ordinary Shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.00 to $218.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Position & filing details for Ehrlichman Matt, PRCH, filed Nov 6, 2026
Sold 0.13% of reported shares15,445,242 before → 15,425,790 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Ehrlichman Matt · CEO, CHAIRMAN AND FOUNDER · Director · 10% owner
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 The sales represented on this Form 4 were effected pursuant to a previously disclosed Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2025 (the "Trading Plan") for personal tax planning purposes and to satisfy tax obligations. The Trading Plan covers the sale of up to an aggregate of 584,998 shares of the Issuer's common stock. All terms of the Trading Plan, including the number of shares to be sold and the minimum sale prices, were fixed at adoption. As of the date of this filing, the Reporting Person has no other Rule 10b5-1 trading plan in effect.
Position & filing details for Foster Jon M, HCA, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
Foster Jon M · EVP and COO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.87 to $514.24, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 Pursuant to a power of substitution, on November 4, 2026, the reporting person transferred 16,142 shares of common stock of the Issuer from a trust to direct ownership in exchange for assets of equal value. The transfer was made at a price per share equal to $503.525 (the average of the high and low prices of shares of common stock of the Issuer on November 4, 2026). The transfer did not change the total number of shares of common stock of the Issuer of which the reporting person may be deemed to have beneficial ownership; however, the shares of common stock previously have been reported by the reporting person as indirectly owned. The reporting person believes that the transfer of shares from the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934.
Position & filing details for Foster Jon M, HCA, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
Foster Jon M · EVP and COO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.87 to $514.24, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 Pursuant to a power of substitution, on November 4, 2026, the reporting person transferred 16,142 shares of common stock of the Issuer from a trust to direct ownership in exchange for assets of equal value. The transfer was made at a price per share equal to $503.525 (the average of the high and low prices of shares of common stock of the Issuer on November 4, 2026). The transfer did not change the total number of shares of common stock of the Issuer of which the reporting person may be deemed to have beneficial ownership; however, the shares of common stock previously have been reported by the reporting person as indirectly owned. The reporting person believes that the transfer of shares from the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934.
Position & filing details for Foster Jon M, HCA, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
Foster Jon M · EVP and COO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.87 to $514.24, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 Pursuant to a power of substitution, on November 4, 2026, the reporting person transferred 16,142 shares of common stock of the Issuer from a trust to direct ownership in exchange for assets of equal value. The transfer was made at a price per share equal to $503.525 (the average of the high and low prices of shares of common stock of the Issuer on November 4, 2026). The transfer did not change the total number of shares of common stock of the Issuer of which the reporting person may be deemed to have beneficial ownership; however, the shares of common stock previously have been reported by the reporting person as indirectly owned. The reporting person believes that the transfer of shares from the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934.
Position & filing details for CHAPLIN ANN C, QCOM, filed Nov 6, 2026
Sold 5.2% of reported shares28,772 before → 27,271 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
CHAPLIN ANN C · EVP, GenCounsel&CorpSecretary
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026.
Position & filing details for O'Day Daniel Patrick, GILD, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
O'Day Daniel Patrick · Chairman & CEO · Director
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
F2 Sale prices for the transactions reported range from $175.05 to $175.35. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F3 The stock options have a four-year vesting schedule. 25% of the stock options vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
Position & filing details for Orn Jonsson Sigurgeir, BETR, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
Orn Jonsson Sigurgeir · Chief Technology Officer
Filing facts
Security
Class A Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $18.80 to $19.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A common stock.
F3 The RSUs were granted on February 11, 2026 and vest quarterly over four years in 16 nearly equal installments, subject to the Reporting Person's continued service with the Issuer.
Position & filing details for Kurtz George, CRWD, filed Nov 6, 2026
Sold 0.03% of reported shares7,279,987 before → 7,277,709 after
Change in this reported direct Class A common stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Kurtz George · PRESIDENT AND CEO · Director
Filing facts
Security
Class A common stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 Includes shares sold pursuant to a 10b5-1 plan adopted on January 16, 2026.
F2 This transaction was executed in multiple trades at prices ranging from $237.82 to $238.41. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Position & filing details for O'Hara Kevin P, HSTM, filed Nov 6, 2026
Sold 17.5% of reported shares22,901 before → 18,901 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
O'Hara Kevin P · Executive Vice President
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 This transaction was executed in multiple trades at prices ranging from $30.00 to $32.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Position & filing details for Collier Michael Manning, HSTM, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
Collier Michael Manning · Executive Vice President
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 This transaction was executed in multiple trades at prices ranging from $30.23 to $31.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F2 The exercise and sale were effected through a broker-assisted cashless exercise.
F3 This transaction was executed in multiple trades at prices ranging from $29.41 to $30.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Position & filing details for ROTHBLATT MARTINE A, UTHR, filed Nov 6, 2026
Sold 0.04% of reported shares325,923 before → 325,803 after
Change in this reported indirect Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership; indirect interests may overlap other reported holdings.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
ROTHBLATT MARTINE A · Chairperson & CEO · Director
Filing facts
Security
Common Stock
Ownership
Indirect · by Trust
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
Position & filing details for Mansueto Joseph D, MORN, filed Nov 6, 2026
Sold 0.03% of reported shares8,592,455 before → 8,589,523 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Mansueto Joseph D · Executive Chairman · Director · 10% owner
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2026.
F2 The transaction was executed in multiple trades at prices ranging from $244.4100 to $245.3400. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.
Position & filing details for Reske James R, FCF, filed Nov 6, 2026
Sold 0.14% of reported shares69,238 before → 69,138 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Reske James R · EVP/Chief Financial Officer
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 Award in 2024 of service based stock units convertible into shares of FCF common stock on a 1-for-1 basis at the end of a 3 year vesting period.
F2 Award in 2025 of service based stock units convertible into shares of FCF common stock on a 1-for-1 basis at the end of a 3 year vesting period.
Award in 2026 of service based stock units convertible into shares of FCF common stock on a 1-for-1 basis at the end of a 3 year vesting period.
Position & filing details for RUBINSTEIN JULIE, ADPT, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
RUBINSTEIN JULIE · President and COO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.26 to $26.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.26 to $26.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Position & filing details for Kurtz George, CRWD, filed Nov 6, 2026
Sold 0.001% of reported shares7,283,109 before → 7,283,009 after
Change in this reported direct Class A common stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Kurtz George · PRESIDENT AND CEO · Director
Filing facts
Security
Class A common stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 Includes shares sold pursuant to a 10b5-1 plan adopted on January 16, 2026.
F2 This transaction was executed in multiple trades at prices ranging from $237.82 to $238.41. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Position & filing details for Reske James R, FCF, filed Nov 6, 2026
Sold 0.09% of reported shares70,098 before → 70,038 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Reske James R · EVP/Chief Financial Officer
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 Award in 2024 of service based stock units convertible into shares of FCF common stock on a 1-for-1 basis at the end of a 3 year vesting period.
F2 Award in 2025 of service based stock units convertible into shares of FCF common stock on a 1-for-1 basis at the end of a 3 year vesting period.
Award in 2026 of service based stock units convertible into shares of FCF common stock on a 1-for-1 basis at the end of a 3 year vesting period.
Position & filing details for King Ryan A, CHYM, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
King Ryan A · Co-Founder · Director
Filing facts
Security
Class A Common Stock
Ownership
Indirect · See footnote
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 The shares are held by the King Family Trust, for which the Reporting Person serves as trustee.
F2 These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2025.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.94 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separated price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.19 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separated price within the range set forth in this footnote.
Position & filing details for Reske James R, FCF, filed Nov 6, 2026
Sold 0.14% of reported shares70,298 before → 70,198 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Reske James R · EVP/Chief Financial Officer
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 Award in 2024 of service based stock units convertible into shares of FCF common stock on a 1-for-1 basis at the end of a 3 year vesting period.
F2 Award in 2025 of service based stock units convertible into shares of FCF common stock on a 1-for-1 basis at the end of a 3 year vesting period.
Award in 2026 of service based stock units convertible into shares of FCF common stock on a 1-for-1 basis at the end of a 3 year vesting period.
Position & filing details for Mansueto Joseph D, MORN, filed Nov 6, 2026
Sold 0.03% of reported shares8,589,523 before → 8,587,275 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Mansueto Joseph D · Executive Chairman · Director · 10% owner
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2026.
F2 The transaction was executed in multiple trades at prices ranging from $244.4100 to $245.3400. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.
Position & filing details for Van de Put Dirk, MDLZ, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
Van de Put Dirk · Chief Executive Officer · Director
Filing facts
Security
Class A Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2026.
F2 The price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.00 to $68.14, inclusive. The reporting person undertakes to provide to Mondelez International, Inc., any security holder of Mondelez International, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
F3 The price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.00 to $68.11, inclusive. The reporting person undertakes to provide to Mondelez International, Inc., any security holder of Mondelez International, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
Position & filing details for Taffe Norman P, GNRC, filed Nov 6, 2026
Sold 1.8% of reported shares10,976 before → 10,776 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Taffe Norman P · President Generac Home
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 Adoption date of referenced 10b5-1(c) plan is: 03-06-2026
Position & filing details for Kurtz George, CRWD, filed Nov 6, 2026
Sold 0.02% of reported shares7,276,479 before → 7,274,809 after
Change in this reported direct Class A common stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Kurtz George · PRESIDENT AND CEO · Director
Filing facts
Security
Class A common stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 Includes shares sold pursuant to a 10b5-1 plan adopted on January 16, 2026.
F2 This transaction was executed in multiple trades at prices ranging from $237.82 to $238.41. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Position & filing details for ROTHBLATT MARTINE A, UTHR, filed Nov 6, 2026
Sold 0.02% of reported shares324,523 before → 324,443 after
Change in this reported indirect Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership; indirect interests may overlap other reported holdings.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
ROTHBLATT MARTINE A · Chairperson & CEO · Director
Filing facts
Security
Common Stock
Ownership
Indirect · by Trust
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
Position & filing details for Kurtz George, CRWD, filed Nov 6, 2026
Sold 0.003% of reported shares7,273,561 before → 7,273,309 after
Change in this reported direct Class A common stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Kurtz George · PRESIDENT AND CEO · Director
Filing facts
Security
Class A common stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 Includes shares sold pursuant to a 10b5-1 plan adopted on January 16, 2026.
F2 This transaction was executed in multiple trades at prices ranging from $237.82 to $238.41. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
SE
SESea Limited American Depositary Shares, each representing one Class A Ordinary Share
Wang YanjunCCO and GC
Sale$6,538Sold 0.13% of reported shares88 shares · $74.30 / share
Position & filing details for Wang Yanjun, SE, filed Nov 6, 2026
Sold 0.13% of reported shares67,126 before → 67,038 after
Change in this reported indirect Class A ordinary shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership; indirect interests may overlap other reported holdings.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Wang Yanjun · CCO and GC
Filing facts
Security
Class A ordinary shares
Ownership
Indirect · By BVI entity
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by a BVI entity controlled by the Reporting Person on March 26, 2026.
F2 Represents the weighted average price of shares sold at prices that ranged from $78.77 to $79.75. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.
Position & filing details for Jackson Benjamin, ICE, filed Nov 6, 2026
Sold 0.25% of reported shares156,932 before → 156,532 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Jackson Benjamin · President
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan which was approved and became effective as of November 3, 2025.
F2 The price range for the aggregate amount sold by the direct holder is $175.00 - $175.04. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price.
Position & filing details for ROTHBLATT MARTINE A, UTHR, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
ROTHBLATT MARTINE A · Chairperson & CEO · Director
Filing facts
Security
Common Stock
Ownership
Indirect · by Trust
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
F10 This transaction was executed in multiple trades at prices ranging from $571.17 to $572.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11 This transaction was executed in multiple trades at prices ranging from $572.17 to $573.12. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
SE
SESea Limited American Depositary Shares, each representing one Class A Ordinary Share
Wang YanjunCCO and GC
Sale$38,403Sold 0.76% of reported shares510 shares · $75.30 / share
Position & filing details for Wang Yanjun, SE, filed Nov 6, 2026
Sold 0.76% of reported shares67,038 before → 66,528 after
Change in this reported indirect Class A ordinary shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership; indirect interests may overlap other reported holdings.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Wang Yanjun · CCO and GC
Filing facts
Security
Class A ordinary shares
Ownership
Indirect · By BVI entity
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by a BVI entity controlled by the Reporting Person on March 26, 2026.
F2 Represents the weighted average price of shares sold at prices that ranged from $78.77 to $79.75. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.
Position & filing details for Keleher Stephen, RDN, filed Nov 6, 2026
Sold 22.4% of reported shares35,789 before → 27,789 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Keleher Stephen · Sr EVP Co-Head Radian Guaranty
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 Pre-arranged sale of common stock pursuant to a 10b5-1 trading plan entered into in June 2026.
F2 Includes 362 shares of common stock acquired through the Radian Group Inc. Employee Stock Purchase Plan on June 30, 2026.
Position & filing details for Ehrlichman Matt, PRCH, filed Nov 6, 2026
Sold 1.2% of reported shares15,634,304 before → 15,445,242 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Ehrlichman Matt · CEO, CHAIRMAN AND FOUNDER · Director · 10% owner
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 The sales represented on this Form 4 were effected pursuant to a previously disclosed Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2025 (the "Trading Plan") for personal tax planning purposes and to satisfy tax obligations. The Trading Plan covers the sale of up to an aggregate of 584,998 shares of the Issuer's common stock. All terms of the Trading Plan, including the number of shares to be sold and the minimum sale prices, were fixed at adoption. As of the date of this filing, the Reporting Person has no other Rule 10b5-1 trading plan in effect.
Position & filing details for Fraga Francisco, MCK, filed Nov 6, 2026
Sold 12.8% of reported shares5,064.496 before → 4,414.496 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Fraga Francisco · EVP, CIO and CTO
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 Sale pursuant to a previously adopted plan dated March 10, 2026, in compliance with Rule 10b5-1(c).
Position & filing details for Reske James R, FCF, filed Nov 6, 2026
Sold 0.14% of reported shares69,638 before → 69,538 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Reske James R · EVP/Chief Financial Officer
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 Award in 2024 of service based stock units convertible into shares of FCF common stock on a 1-for-1 basis at the end of a 3 year vesting period.
F2 Award in 2025 of service based stock units convertible into shares of FCF common stock on a 1-for-1 basis at the end of a 3 year vesting period.
Award in 2026 of service based stock units convertible into shares of FCF common stock on a 1-for-1 basis at the end of a 3 year vesting period.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $498.54 to $499.53, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.55 to $498.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $496.55 to $497.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $495.49 to $496.47, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $494.43 to $495.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $492.50 to $494.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $491.46 to $492.36, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 The stock appreciation rights vested in four equal annual installments beginning on January 29, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.02 to $219.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.00 to $220.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.00 to $221.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.00 to $222.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.00 to $223.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.00 to $224.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $498.54 to $499.53, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.55 to $498.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $496.55 to $497.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $495.49 to $496.47, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $494.43 to $495.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $492.50 to $494.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $491.46 to $492.36, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 The stock appreciation rights vested in four equal annual installments beginning on January 29, 2021.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $498.54 to $499.53, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.55 to $498.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $496.55 to $497.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $495.49 to $496.47, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $494.43 to $495.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $492.50 to $494.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $491.46 to $492.36, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 The stock appreciation rights vested in four equal annual installments beginning on January 29, 2021.
F4 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.55 to $26.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $27.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.59 to $27.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F7 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.65 to $27.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F8 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.65 to $28.04, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $498.54 to $499.53, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.55 to $498.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $496.55 to $497.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $495.49 to $496.47, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $494.43 to $495.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $492.50 to $494.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $491.46 to $492.36, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 The stock appreciation rights vested in four equal annual installments beginning on January 29, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.02 to $219.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.00 to $220.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.00 to $221.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.00 to $222.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.00 to $223.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.00 to $224.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.02 to $219.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.00 to $220.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.00 to $221.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.00 to $222.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.00 to $223.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.00 to $224.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.02 to $219.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.00 to $220.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.00 to $221.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.00 to $222.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.00 to $223.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.00 to $224.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.55 to $26.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $27.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.59 to $27.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F7 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.65 to $27.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F8 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.65 to $28.04, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.02 to $219.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.00 to $220.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.00 to $221.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.00 to $222.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.00 to $223.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.00 to $224.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.02 to $219.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.00 to $220.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.00 to $221.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.00 to $222.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.00 to $223.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.00 to $224.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.02 to $219.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.00 to $220.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.00 to $221.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.00 to $222.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.00 to $223.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.00 to $224.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.05 to $21.93 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.26 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.98 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.43 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 Following the reported transactions, the Reporting Person beneficially owns 21,166,096 shares of the Issuer's common stock, including 6,416,712 shares held by West Equities, LLC, representing approximately 18.5% of the Issuer's outstanding common stock. This amount excludes 676,406 restricted stock units that are scheduled to vest more than 60 days following the date of this Form 4 and therefore are not included in the Reporting Person's beneficial ownership.
F7 Issuer common stock held by West Equities, LLC over which Reporting Person has sole voting and dispositive power.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $498.54 to $499.53, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.55 to $498.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $496.55 to $497.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $495.49 to $496.47, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $494.43 to $495.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $492.50 to $494.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $491.46 to $492.36, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 The stock appreciation rights vested in four equal annual installments beginning on January 29, 2021.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $498.54 to $499.53, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.55 to $498.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $496.55 to $497.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $495.49 to $496.47, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $494.43 to $495.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $492.50 to $494.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $491.46 to $492.36, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 The stock appreciation rights vested in four equal annual installments beginning on January 29, 2021.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $498.54 to $499.53, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.55 to $498.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $496.55 to $497.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $495.49 to $496.47, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $494.43 to $495.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $492.50 to $494.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $491.46 to $492.36, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 The stock appreciation rights vested in four equal annual installments beginning on January 29, 2021.
F3 Includes shares to be issued in connection with the vesting of one or more restricted stock units (RSUs).
F4 This transaction was executed in multiple trades at prices ranging from $239.64 to $240.34. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $240.64 to $241.62. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6 This transaction was executed in multiple trades at prices ranging from $241.71 to $242.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7 This transaction was executed in multiple trades at prices ranging from $242.77 to $243.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8 This transaction was executed in multiple trades at prices ranging from $243.77 to $244.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9 This transaction was executed in multiple trades at prices ranging from $245.05 to $245.84. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F10 This transaction was executed in multiple trades at prices ranging from $246.44 to $247.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11 This transaction was executed in multiple trades at prices ranging from $247.45 to $248.28. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F12 This transaction was executed in multiple trades at prices ranging from $248.61 to $249.34. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F13 This transaction was executed in multiple trades at prices ranging from $250.45 to $250.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F14 This transaction was executed in multiple trades at prices ranging from $251.73 to $252.40. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F15 This transaction was executed in multiple trades at prices ranging from $214.06 to $214.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F16 This transaction was executed in multiple trades at prices ranging from $215.70 to $215.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F17 This transaction was executed in multiple trades at prices ranging from $216.48 to $217.47. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F18 This transaction was executed in multiple trades at prices ranging from $217.56 to $218.55. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F19 This transaction was executed in multiple trades at prices ranging from $218.57 to $219.52. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F20 This transaction was executed in multiple trades at prices ranging from $219.62 to $220.59. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F21 This transaction was executed in multiple trades at prices ranging from $220.76 to $221.61. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F22 This transaction was executed in multiple trades at prices ranging from $222.23 to $222.62. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F23 The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest therein.
F4 The options vested according to the following schedule: 15% vested on December 9, 2021, 20% vested on December 9, 2022, 30% vested on December 9, 2023, and the remaining 35% vested on December 9, 2024.
F10 This transaction was executed in multiple trades at prices ranging from $602.02 to $602.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11 Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F12 Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F13 Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F2 This transaction was executed in multiple trades at prices ranging from $592.58 to $593.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F4 This transaction was executed in multiple trades at prices ranging from $594.00 to $594.875. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $595.23 to $595.97. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6 This transaction was executed in multiple trades at prices ranging from $596.44 to $597.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7 This transaction was executed in multiple trades at prices ranging from $597.46 to $598.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8 This transaction was executed in multiple trades at prices ranging from $598.53 to $599.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9 This transaction was executed in multiple trades at prices ranging from $600.93 to $601.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The transaction was executed in multiple trades at prices ranging from $245.4900 to $246.4800. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.
F4 The transaction was executed in multiple trades at prices ranging from $246.4900 to $247.4500. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.
F5 The transaction was executed in multiple trades at prices ranging from $247.4950 to $248.4400. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.
F6 The shares are held in grantor retained annuity trusts for the benefit of the reporting person and his children. The reporting person serves as trustee of the grantor retained annuity trusts.
F7 The shares are held in trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts.
F4 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.55 to $26.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $27.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.59 to $27.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F7 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.65 to $27.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F8 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.65 to $28.04, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3 Includes shares to be issued in connection with the vesting of one or more restricted stock units (RSUs).
F4 This transaction was executed in multiple trades at prices ranging from $239.64 to $240.34. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $240.64 to $241.62. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6 This transaction was executed in multiple trades at prices ranging from $241.71 to $242.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7 This transaction was executed in multiple trades at prices ranging from $242.77 to $243.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8 This transaction was executed in multiple trades at prices ranging from $243.77 to $244.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9 This transaction was executed in multiple trades at prices ranging from $245.05 to $245.84. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F10 This transaction was executed in multiple trades at prices ranging from $246.44 to $247.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11 This transaction was executed in multiple trades at prices ranging from $247.45 to $248.28. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F12 This transaction was executed in multiple trades at prices ranging from $248.61 to $249.34. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F13 This transaction was executed in multiple trades at prices ranging from $250.45 to $250.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F14 This transaction was executed in multiple trades at prices ranging from $251.73 to $252.40. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F15 This transaction was executed in multiple trades at prices ranging from $214.06 to $214.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F16 This transaction was executed in multiple trades at prices ranging from $215.70 to $215.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F17 This transaction was executed in multiple trades at prices ranging from $216.48 to $217.47. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F18 This transaction was executed in multiple trades at prices ranging from $217.56 to $218.55. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F19 This transaction was executed in multiple trades at prices ranging from $218.57 to $219.52. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F20 This transaction was executed in multiple trades at prices ranging from $219.62 to $220.59. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F21 This transaction was executed in multiple trades at prices ranging from $220.76 to $221.61. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F22 This transaction was executed in multiple trades at prices ranging from $222.23 to $222.62. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F23 The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest therein.
F5 Certain of these securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F6 Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
F7 The shares are held by King Irrevocable Trust A, for which the Reporting Person serves as attorney-in-fact.
F8 The shares are held by King Irrevocable Trust M, for which the Reporting Person serves as attorney-in-fact.
F9 The shares are held by King Grantor Trust MV, for which the Reporting Person serves as attorney-in-fact.
F10 The shares are held by King Gift Trust AK, for which the Reporting Person serves as attorney-in-fact.
F11 The shares are held by King Gift Trust AV, for which the Reporting Person serves as attorney-in-fact.
F12 The shares are held by King Gift Trust CV, for which the Reporting Person serves as attorney-in-fact.
F13 The shares are held by King Gift Trust MK, for which the Reporting Person serves as attorney-in-fact.
F14 The shares are held by King Gift Trust NV, for which the Reporting Person serves as attorney-in-fact.
F15 The shares are held by Maureen Vergara, a member of the Reporting Person's family.
F3 The transaction was executed in multiple trades at prices ranging from $245.4900 to $246.4800. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.
F4 The transaction was executed in multiple trades at prices ranging from $246.4900 to $247.4500. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.
F5 The transaction was executed in multiple trades at prices ranging from $247.4950 to $248.4400. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.
F6 The shares are held in grantor retained annuity trusts for the benefit of the reporting person and his children. The reporting person serves as trustee of the grantor retained annuity trusts.
F7 The shares are held in trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts.
F4 This Form 4 is being filed to report the exercise of stock options that became 100% exercisable on February 22, 2021 and expire on February 22, 2028.
F3 Includes shares to be issued in connection with the vesting of one or more restricted stock units (RSUs).
F4 This transaction was executed in multiple trades at prices ranging from $239.64 to $240.34. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $240.64 to $241.62. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6 This transaction was executed in multiple trades at prices ranging from $241.71 to $242.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7 This transaction was executed in multiple trades at prices ranging from $242.77 to $243.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8 This transaction was executed in multiple trades at prices ranging from $243.77 to $244.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9 This transaction was executed in multiple trades at prices ranging from $245.05 to $245.84. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F10 This transaction was executed in multiple trades at prices ranging from $246.44 to $247.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11 This transaction was executed in multiple trades at prices ranging from $247.45 to $248.28. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F12 This transaction was executed in multiple trades at prices ranging from $248.61 to $249.34. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F13 This transaction was executed in multiple trades at prices ranging from $250.45 to $250.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F14 This transaction was executed in multiple trades at prices ranging from $251.73 to $252.40. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F15 This transaction was executed in multiple trades at prices ranging from $214.06 to $214.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F16 This transaction was executed in multiple trades at prices ranging from $215.70 to $215.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F17 This transaction was executed in multiple trades at prices ranging from $216.48 to $217.47. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F18 This transaction was executed in multiple trades at prices ranging from $217.56 to $218.55. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F19 This transaction was executed in multiple trades at prices ranging from $218.57 to $219.52. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F20 This transaction was executed in multiple trades at prices ranging from $219.62 to $220.59. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F21 This transaction was executed in multiple trades at prices ranging from $220.76 to $221.61. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F22 This transaction was executed in multiple trades at prices ranging from $222.23 to $222.62. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F23 The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest therein.
F10 This transaction was executed in multiple trades at prices ranging from $602.02 to $602.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11 Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F12 Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F13 Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F2 This transaction was executed in multiple trades at prices ranging from $592.58 to $593.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F4 This transaction was executed in multiple trades at prices ranging from $594.00 to $594.875. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $595.23 to $595.97. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6 This transaction was executed in multiple trades at prices ranging from $596.44 to $597.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7 This transaction was executed in multiple trades at prices ranging from $597.46 to $598.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8 This transaction was executed in multiple trades at prices ranging from $598.53 to $599.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9 This transaction was executed in multiple trades at prices ranging from $600.93 to $601.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 Includes shares to be issued in connection with the vesting of one or more restricted stock units (RSUs).
F4 This transaction was executed in multiple trades at prices ranging from $239.64 to $240.34. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $240.64 to $241.62. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6 This transaction was executed in multiple trades at prices ranging from $241.71 to $242.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7 This transaction was executed in multiple trades at prices ranging from $242.77 to $243.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8 This transaction was executed in multiple trades at prices ranging from $243.77 to $244.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9 This transaction was executed in multiple trades at prices ranging from $245.05 to $245.84. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F10 This transaction was executed in multiple trades at prices ranging from $246.44 to $247.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11 This transaction was executed in multiple trades at prices ranging from $247.45 to $248.28. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F12 This transaction was executed in multiple trades at prices ranging from $248.61 to $249.34. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F13 This transaction was executed in multiple trades at prices ranging from $250.45 to $250.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F14 This transaction was executed in multiple trades at prices ranging from $251.73 to $252.40. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F15 This transaction was executed in multiple trades at prices ranging from $214.06 to $214.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F16 This transaction was executed in multiple trades at prices ranging from $215.70 to $215.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F17 This transaction was executed in multiple trades at prices ranging from $216.48 to $217.47. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F18 This transaction was executed in multiple trades at prices ranging from $217.56 to $218.55. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F19 This transaction was executed in multiple trades at prices ranging from $218.57 to $219.52. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F20 This transaction was executed in multiple trades at prices ranging from $219.62 to $220.59. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F21 This transaction was executed in multiple trades at prices ranging from $220.76 to $221.61. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F22 This transaction was executed in multiple trades at prices ranging from $222.23 to $222.62. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F23 The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest therein.
F3 The common stock number referred in Table I is an aggregate number and represents 134,533 shares of common stock and 17,204 unvested restricted stock units ("RSUs"), and 4,795 performance based restricted stock units ("PSUs"), for which the performance period has been satisfied. The RSUs and PSUs vest over a three-year period, in which 33.33% of the units vest each year.
F4 The satisfaction of the 2024, 2025 and 2026 three-year total shareholder return (TSR) PSUs and the corresponding number of shares to be issued pursuant to these awards, will not be determined until February 2027, February 2028 and February 2029, respectively, and will be reported at the time of vesting. The satisfaction of the 2024, 2025 and 2026 year-three earnings before interest, taxes, depreciation, and amortization (EBITDA) PSUs and the corresponding number of shares to be issued pursuant to these awards, will not be determined until February 2027, February 2028 and February 2029, respectively, and will be reported at the time of vesting.
F5 The satisfaction of the performance based restricted stock units granted as Deal Incentive Awards and the corresponding number of shares to be issued pursuant to these awards, will not be determined until December 2026, December 2027 and December 2028 and will be subject to additional time-based vesting conditions and, if applicable, a subsequent one-year holding period.
F12 This transaction was executed in multiple trades at prices ranging from $573.28 to $574.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F13 This transaction was executed in multiple trades at prices ranging from $574.30 to $575.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F14 This transaction was executed in multiple trades at prices ranging from $575.51 to $576.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F15 This transaction was executed in multiple trades at prices ranging from $576.51 to $577.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F16 This transaction was executed in multiple trades at prices ranging from $577.67 to $578.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F17 This transaction was executed in multiple trades at prices ranging from $578.85 to $579.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F18 This transaction was executed in multiple trades at prices ranging from $580.16 to $580.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F19 This transaction was executed in multiple trades at prices ranging from $581.16 to $582.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F20 This transaction was executed in multiple trades at prices ranging from $582.28 to $583.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F21 This transaction was executed in multiple trades at prices ranging from $584.13 to $584.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F22 This transaction was executed in multiple trades at prices ranging from $585.38 to $586.215. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F23 This transaction was executed in multiple trades at prices ranging from $586.53 to $587.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F24 This transaction was executed in multiple trades at prices ranging from $589.24 to $590.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F25 This transaction was executed in multiple trades at prices ranging from $591.30 to $591.84. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F26 Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F27 Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F28 Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F29 These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023.
F3 This transaction was executed in multiple trades at prices ranging from $562.18 to $563.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F30 Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
F4 This transaction was executed in multiple trades at prices ranging from $563.57 to $564.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $565.08 to $565.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6 This transaction was executed in multiple trades at prices ranging from $566.33 to $566.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7 This transaction was executed in multiple trades at prices ranging from $567.53 to $568.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8 This transaction was executed in multiple trades at prices ranging from $568.54 to $569.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9 This transaction was executed in multiple trades at prices ranging from $569.99 to $570.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.05 to $21.93 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.26 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.98 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.43 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 Following the reported transactions, the Reporting Person beneficially owns 21,166,096 shares of the Issuer's common stock, including 6,416,712 shares held by West Equities, LLC, representing approximately 18.5% of the Issuer's outstanding common stock. This amount excludes 676,406 restricted stock units that are scheduled to vest more than 60 days following the date of this Form 4 and therefore are not included in the Reporting Person's beneficial ownership.
F7 Issuer common stock held by West Equities, LLC over which Reporting Person has sole voting and dispositive power.
